Literature DB >> 11168949

Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells.

S Chen1, M P Cohen, G T Lautenslager, C W Shearman, F N Ziyadeh.   

Abstract

BACKGROUND: The activation of protein kinase C (PKC) and transforming growth factor-beta (TGF-beta) in glomerular mesangial cells has been linked to mesangial matrix expansion in diabetic nephropathy. The role of these mediators in affecting the changes associated with diabetes in the biology of glomerular endothelial cells (GEnCs), which synthesize components of the glomerular basement membrane, is not known. We postulated that the PKC and TGF-beta systems promote the increased endothelial cell synthesis of glomerular basement membrane that is evoked by Amadori-modified glycated albumin, which is present in elevated concentrations in diabetes.
METHODS: We examined the effects of PKC inhibition on collagen IV and TGF-beta1 production by mouse GEnCs incubated with glycated albumin and the influence of glycated albumin on PKC activity, TGF-beta 1 production, and proliferation by these cells.
RESULTS: In physiologic (5.5 mmol/L) glucose concentrations, glycated albumin caused an increase in type IV collagen production that was totally prevented by a general PKC inhibitor GF 109203X (GFX), but only partly prevented by a neutralizing anti-TGF-beta antibody. Glycated albumin increased the steady-state level of TGF-beta 1 mRNA and stimulated the production of TGF-beta 1 protein, which was also prevented by the PKC inhibitor GFX. Of note, glycated albumin significantly stimulated PKC activity, as measured by the phosphorylation of a PKC-specific substrate. Cell proliferation, measured by [(3)H]-thymidine incorporation and cell counting, was decreased in the presence of glycated albumin. This effect was completely prevented by GFX and partially reversed by anti-TGF-beta antibody. Exogenous TGF-beta 1 inhibited cell proliferation to a degree similar to that of glycated albumin.
CONCLUSIONS: PKC signaling and consequent TGF-beta 1 activation participate in the glycated albumin-induced stimulation of basement membrane collagen production by GEnC. By reducing the proliferative capacity, which is likely mediated by PKC and partly by TGF-beta, glycated albumin impedes the ability of the glomerular capillary endothelium to act as a first line of defense against deleterious circulating factors in the diabetic state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168949     DOI: 10.1046/j.1523-1755.2001.059002673.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease.

Authors:  Joanne E Murphy-Ullrich
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 2.  Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.

Authors:  Mark E Williams
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

3.  Binding of Amadori glucose-modified albumin by the monocytic cell line MonoMac 6 activates protein kinase C epsilon protein tyrosine kinases and the transcription factors AP-1 and NF-kappaB.

Authors:  R Salazar; R Brandt; S Krantz
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

Review 4.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

Review 5.  MicroRNAs and their role in progressive kidney diseases.

Authors:  Mitsuo Kato; Laura Arce; Rama Natarajan
Journal:  Clin J Am Soc Nephrol       Date:  2009-07       Impact factor: 8.237

6.  Fructose and moderately high dietary salt-induced hypertension: prevention by a combination of N-acetylcysteine and L-arginine.

Authors:  Sudesh Vasdev; Vicki D Gill; Edward Randell; Yingchun Han; Veeresh Gadag
Journal:  Mol Cell Biochem       Date:  2009-09-26       Impact factor: 3.396

Review 7.  Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications.

Authors:  Margo P Cohen; Fuad N Ziyadeh; Sheldon Chen
Journal:  J Lab Clin Med       Date:  2006-05

Review 8.  Amadori albumin in diabetic nephropathy.

Authors:  Km Neelofar; Jamal Ahmad
Journal:  Indian J Endocrinol Metab       Date:  2015 Jan-Feb

9.  Conformational transitions and glycation of serum albumin in patients with minimal-change glomerulopathy.

Authors:  Sae Yong Hong; Eun Young Lee; Jong Oh Yang; Tae Yeong Kim; Eun Hee Kim; Mi Young Cheong; Soo Hyun Kim; Chae Joon Cheong
Journal:  Korean J Intern Med       Date:  2004-09       Impact factor: 2.884

10.  Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats.

Authors:  Margo P Cohen; Clyde W Shearman
Journal:  Physiol Rep       Date:  2013-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.